{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:54:36Z","timestamp":1772859276125,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:p>The cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV\u2010seropositive allogeneic hematopoietic stem cell transplantation recipients. In a phase III trial (NCT02137772), letermovir significantly reduced clinically significant CMV infection (CS\u2010CMVi) rate vs. placebo through Week 24 (primary end point) and Week 14 (secondary end point) post transplantation. Here, exposure\u2013response relationships were investigated using efficacy and selected safety end points from the phase III trial to inform the proposed clinical dose. <jats:italic>Post hoc<\/jats:italic> exposure estimates were derived from a population pharmacokinetic model. No significant exposure dependencies were found for CS\u2010CMVi through Week 24 or Week 14 among letermovir\u2010treated participants. Evaluated covariates had no impact on exposure\u2013efficacy relationships and letermovir plasma exposure did not affect time of CS\u2010CMVi onset. There was no dependence between adverse event incidence and letermovir exposure. These results support current dosing recommendations in several countries and regions, including the United States and European Union.<\/jats:p>","DOI":"10.1002\/cpt.2456","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T14:56:32Z","timestamp":1634828192000},"page":"485-495","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exposure\u2013Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients"],"prefix":"10.1111","volume":"111","author":[{"given":"Marita","family":"Prohn","sequence":"first","affiliation":[{"name":"qPharmetra LLC Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn R.","family":"Cho","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Viberg","sequence":"additional","affiliation":[{"name":"qPharmetra LLC Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Dykstra","sequence":"additional","affiliation":[{"name":"qPharmetra LLC Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Davis","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Sabato","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Stone","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Badshah","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Leavitt","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Fancourt","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeraj","family":"Macha","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc. Kenilworth New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2010.01.008"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.305"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.1999.010305.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15515"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30107-0"},{"key":"e_1_2_10_8_1","volume-title":"Prevymis","author":"[highlights of prescribing information]. (Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 2021)"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00507"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.19.9077-9086.2001"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S180908"},{"key":"e_1_2_10_14_1","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez D.P.","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"e_1_2_10_15_1","volume-title":"Prevymis [summary of product characteristics]","author":"Merck Sharp & Dohme Ltd., London, UK,","year":"2020"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309533"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13376"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13292"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12225"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.388"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1423"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12593"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2057-6"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_2_10_25_1","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"key":"e_1_2_10_26_1","volume-title":"Cytovene\u2010IV [highlights of prescribing information]","author":"Genentech USA, Inc","year":"2018"},{"key":"e_1_2_10_27_1","volume-title":"Valcyte [prescribing information]","author":"(Genentech USA, Inc"},{"key":"e_1_2_10_28_1","volume-title":"Foscavir [prescribing information]","author":"(Clinigen Group PLC","year":"2020"},{"key":"e_1_2_10_29_1","volume-title":"Vistide [prescribing information]","author":"(Gilead Sciences, Inc","year":"2010"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2456","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2456","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:30:50Z","timestamp":1699363850000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/cpt.2456"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2456","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"2021-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}